Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) shares traded down 3.7% during mid-day trading on Wednesday . The stock traded as low as $2.78 and last traded at $2.83, with a volume of 1,027,696 shares traded. The stock had previously closed at $2.94.

Separately, Maxim Group cut their price target on Adamis Pharmaceuticals Corp. from $17.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, July 21st.

The firm’s 50-day moving average is $2.88 and its 200 day moving average is $5.29. The stock’s market capitalization is $57.44 million.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.